Telix Pharmaceuticals (TLX) Receivables - Other (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Receivables - Other data on file, last reported at $1.3 million in Q4 2025.

• Receivables - Other for Q4 2025 came in at $1.3 million, down 24.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.3 million (down 24.37% YoY), and the FY2025 annual result was $1.3 million, down 27.22% from the prior year.
• Receivables - Other eased to $1.3 million in Q4 2025 per TLX's latest filing, from $1.7 million in the prior quarter.
• Over five years, Receivables - Other peaked at $1.7 million in Q4 2024 and troughed at $1.3 million in Q4 2025.
• A 3-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other climbed 10.53% in 2024, then declined 24.37% in 2025.
• A 3-year view of Receivables - Other shows it stood at $1.5 million in 2023, then rose by 10.53% to $1.7 million in 2024, then slipped by 24.37% to $1.3 million in 2025.
• Business Quant data shows TLX's Receivables - Other at $1.3 million in Q4 2025, $1.7 million in Q4 2024, and $1.5 million in Q4 2023.